DEF 14A: Tenax Therapeutics Seeks Stockholder Approval for Increased Share Issuance Under Incentive Plan

Tenax Therapeutics is holding its annual meeting on June 7, 2024, to vote on director elections, an amendment to the stock incentive plan, and ratification of its accounting firm.

Summary

• Tenax Therapeutics will hold its Annual Meeting of Stockholders on June 7, 2024, at its Chapel Hill, North Carolina headquarters.
• Stockholders of record as of April 11, 2024, are eligible to vote.
• The meeting will address the election of directors for a one-year term expiring in 2025.
• A key proposal involves Amendment No. 1 to the 2022 Stock Incentive Plan, seeking to increase the authorized shares by 400,000, bringing the total to 400,688 shares.
• This increase represents approximately 20% of the company's outstanding shares as of April 11, 2024.
• The company believes this increase will cover equity compensation needs for about two years.
• Stockholders will also vote to ratify the appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting 'FOR' all proposals.

Sentiment

Score: 7

Explanation: The document is primarily procedural, outlining the agenda for the annual meeting. The sentiment is neutral to slightly positive, as the proposals aim to support the company's long-term growth and attract talent.

Positives

• The proposed increase in shares for the 2022 Stock Incentive Plan aims to align employee, director, and service provider interests with the company's growth and stockholder value.
• The company believes the increased share reserve will be sufficient for approximately two years of equity compensation needs.
• The Board of Directors is actively engaged in risk oversight and has delegated certain functions to committees.
• The company has a Code of Ethics and Business Conduct applicable to all officers, directors, and employees.

Negatives

• If stockholder approval for the plan amendment is not received, the current 2022 Plan will remain in effect without the amendment, potentially limiting the company's ability to offer competitive equity compensation.
• The company does not currently have a policy that prohibits our directors, officers and employees from engaging in hedging activity in our securities or pledging any of our securities as collateral for loans or margin accounts.

Risks

• Failure to secure stockholder approval for the proposed amendment to the 2022 Stock Incentive Plan could hinder the company's ability to attract and retain key personnel.
• The company operates in a highly complex and regulated industry, exposing it to various operational, financial, legal, and regulatory risks.
• The company's success depends on the progress of its clinical trials and regulatory approvals.

Future Outlook

The company anticipates that the proposed increase in shares authorized for issuance under the 2022 Plan will be sufficient to meet its equity compensation requirements for approximately two years from the date of the Annual Meeting.

Industry Context

As a biopharmaceutical company, Tenax Therapeutics relies on equity compensation to attract and retain talent in a competitive industry. Increasing the share reserve under the incentive plan is a common practice to ensure the company can continue to offer competitive compensation packages.

Comparison to Industry Standards

• Increasing share reserves for equity compensation plans is a common practice among publicly traded biopharmaceutical companies to attract and retain talent.
• Comparable companies such as RedHill Biopharma, Avalo Therapeutics, and Portage Biotech also utilize stock incentive plans to align employee and shareholder interests.
• The percentage of outstanding shares requested for the increase (approximately 20%) is within the typical range for companies in this sector.

Related Party Transactions

• In May 2022, Tenax Therapeutics entered into a securities purchase agreement with Armistice Capital, LLC, a then-affiliate, for a private placement of units consisting of pre-funded warrants and warrants, resulting in net proceeds of approximately $7.9 million.

Stakeholder Impact

• Approval of the stock incentive plan amendment could positively impact employees, directors, and service providers by providing them with a greater stake in the company's success.
• Stockholders could benefit from the company's ability to attract and retain talent, potentially leading to increased long-term value.
• The ratification of the independent auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders need to review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 7, 2024, and announce the voting results.
• The company will implement the approved proposals, including the amendment to the stock incentive plan.

Key Dates

Keywords

stockholders, annual meeting, proxy statement, directors, stock incentive plan, equity compensation, Cherry Bekaert, independent auditor, Tenax Therapeutics